Short Interest in Kazia Therapeutics Limited (NASDAQ:KZIA) Decreases By 34.1%

Kazia Therapeutics Limited (NASDAQ:KZIA) was the target of a large decrease in short interest in the month of February. As of February 28th, there was short interest totalling 59,600 shares, a decrease of 34.1% from the February 13th total of 90,500 shares. Based on an average trading volume of 1,860,000 shares, the short-interest ratio is presently 0.0 days. Approximately 2.1% of the shares of the stock are short sold.

Analyst Upgrades and Downgrades

Separately, Maxim Group assumed coverage on Kazia Therapeutics in a report on Thursday, February 6th. They issued a “buy” rating and a $3.00 price target on the stock.

Institutional Investors Weigh In On Kazia Therapeutics

An institutional investor recently bought a new position in Kazia Therapeutics stock. Barclays PLC purchased a new position in shares of Kazia Therapeutics Limited (NASDAQ:KZIA) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 120,000 shares of the company’s stock, valued at approximately $212,000. Barclays PLC owned 2.38% of Kazia Therapeutics as of its most recent SEC filing. 30.89% of the stock is owned by institutional investors.

Kazia Therapeutics Stock Performance

Shares of KZIA traded up $0.00 on Monday, reaching $1.00. The stock had a trading volume of 66,249 shares, compared to its average volume of 853,284. Kazia Therapeutics has a twelve month low of $0.76 and a twelve month high of $15.80. The firm has a 50-day moving average of $1.20 and a 200 day moving average of $3.18.

Kazia Therapeutics Company Profile

Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company’s lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3.